11/02/2026 Biofrontera's sNDA for Ameluz® PDT in Superficial Basal Cell Carcinoma has been accepted by the US FDA Biofrontera's sNDA for Ameluz® PDT in Superficial Basal Cell Carcinoma has been accepted by the US FDA ( Ref ) The US FDA completed its filing review and accepted filing of Biofrontera's supplemental New Drug Application (sNDA) for Ameluz® (aminolevulinic acid hydrochloride) topical gel used in combination with the RhodoLED® red-light lamp series for the treatment

08/08/2025 Boehringer Ingelheim's Hernexeos received accelerated approval from the US FDA for HER2-mutant advanced NSCLC ( Ref ) The US...